Luscii Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Luscii's estimated annual revenue is currently $28.1M per year.(i)
  • Luscii's estimated revenue per employee is $270,000

Employee Data

  • Luscii has 104 Employees.(i)
  • Luscii grew their employee count by 21% last year.

Luscii's People

NameTitleEmail/Phone
1
FounderReveal Email/Phone
2
Co Founder & CFOReveal Email/Phone
3
Co-Founder - Creating space for careReveal Email/Phone
4
Head Product - InteroperabilityReveal Email/Phone
5
Director Strategic PartnershipsReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Product Owner & People Lead LinkReveal Email/Phone
8
Senior Product OwnerReveal Email/Phone
9
Technical Product Owner and DevOps specialistReveal Email/Phone
10
Information Security Manager, Compliance & EventsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31.1M11513%N/AN/A
#2
$109.4M3248%N/AN/A
#3
$51.1M17224%N/AN/A
#4
$329.6M8727%N/AN/A
#5
$24.3M90-2%N/AN/A
#6
$67.1M2261%N/AN/A
#7
$86.7M29222%N/AN/A
#8
$296.4M7843%N/AN/A
#9
$21.6M80-66%N/AN/A
#10
$35.6M132-1%N/AN/A
Add Company

What Is Luscii?

That sympathetic lady who was in the hospital for decompensation? That frightened man with COPD who doesn't want to bother his daughter? Will they make it at home alone till the next regular hospital check up? Luscii telemonitoring is the digital partner in your care team. Together we prevent A&E visits, admissions and unnecessary outpatient clinic visits. Your expertise. Our technology.

keywords:N/A

N/A

Total Funding

104

Number of Employees

$28.1M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Luscii News

2022-04-20 - Isala ontwikkelt app voor dialysepatiënten

“Zodra wij een nieuwe patiënt aanmelden, belt een medewerker van Luscii met deze patiënt en helpt hem of haar met het installeren van de app.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.1M1041%N/A
#2
$7.5M10416%N/A
#3
$21M10437%N/A
#4
$15.1M10421%N/A
#5
$15.1M104N/AN/A